| Michael D. Wyzga |
Currently, Michael D. Wyzga holds the position of Chief Financial Officer & Senior Vice President for Yumanity Therapeutics, Inc.
He received an undergraduate degree from Lehigh University and an MBA from SC Johnson College of Business. |
| Brigitte Robertson |
Dr. Brigitte Robertson, MD, is a Chief Medical Officer at Yumanity Therapeutics, Inc. and a Chief Medical Officer at Yumanity, Inc. Dr. Robertson was previously employed as a Chief Medical Officer by Neurovance, Inc., a Senior Director & Development Strategy Team Lead by Shire Pharmaceuticals, Inc., and a Principal by Children's Community Pediatrics. She received her undergraduate degree from Georgia State University and a doctorate degree from Georgia Health Sciences University. |
| Paulash Mohsen |
Mr. Paulash Mohsen is a Chief Business Officer at Yumanity Therapeutics, Inc. and a Chief Business Officer at Yumanity, Inc. Mr. Mohsen was previously employed as a Vice President-Strategy by Pfizer Inc., a Country Manager-Canada Region by Cubist Pharmaceuticals LLC, and a Vice President-Strategy & Business Operations by Optimer Pharmaceuticals LLC. He received his undergraduate degree from Brown University, a graduate degree from Massachusetts Institute of Technology and an MBA from Harvard Business School. |
| Ellen K. Forest |
Presently, Ellen K. Forest occupies the position of Chief Human Resources Officer at Yumanity Therapeutics, Inc.
She previously was Vice President & Head-Human Resources at Merrimack Pharmaceuticals, Inc., Director at Egon Zehnder International, Inc., Senior Vice President & Head-Human Capital at Cogen Immune Medicine, Inc., Director-Human Resources at TA Associates Management LP, Director-Human Resources for Baxalta, Inc. and Manager-Human Resources at Mass General Brigham, Inc.
She received an undergraduate degree and a graduate degree from Emmanuel College, Inc. |
| N. Anthony Coles |
Dr. N. A. Coles is an Executive Chairman & Chief Executive Officer at Cerevel Therapeutics LLC, a Chief Executive Officer & Director at Cerevel Therapeutics, Inc., an Executive Chairman & Chief Executive Officer at Cerevel Therapeutics Holdings, Inc., an Independent Director at Regeneron Pharmaceuticals, Inc., a Council Member at Smithsonians National Museum of Natural History, a Member at Harvard Medical School and a Non-Executive Chairman at Yumanity Therapeutics, Inc. He is on the Board of Directors at Cerevel Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Johns Hopkins Medicine, Inc., Biotechnology Innovation Organization, Council on Foreign Relations, Inc., The United States Olympic Endowment, Yumanity, Inc., Boston Medical Center, The Johns Hopkins University and The Metropolitan Museum of Art. Dr. Coles was previously employed as a Chairman by CRISPR Therapeutics AG, an Executive Chairman by Yumanity, Inc., an Independent Director by McKesson Corp., a Chairman & Chief Executive Officer by Trate Enterprises, LLC, an Independent Director by Laboratory Corp. of America Holdings, an Independent Director by Campus Crest Communities, Inc., a President & Chief Executive Officer by Onyx Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by NPS Pharmaceuticals, Inc., a Senior Vice President-Commercial Operations by Vertex Pharmaceuticals, Inc., a Senior Vice President-Strategy & Policy by Bristol Myers Squibb Co., and a VP-Hypertension & Heart Failure Business Group by Merck & Co., Inc. He also served on the board at Seragon Pharmaceuticals, Inc., FoldRx Pharmaceuticals, Inc. and Yumanity Holdings LLC. He received his undergraduate degree from The Johns Hopkins University, a graduate degree from Harvard University and a doctorate degree from Duke University. |
| Marie N. Epstein |
Founder of Volition Capital LLC, Marie N. Epstein presently is Vice President-Finance of Yumanity Therapeutics, Inc. and Vice President-Finance of Yumanity, Inc. (a subsidiary of Yumanity Therapeutics, Inc.). She is also Vice President-Finance for Yumanity, Inc.
In the past Marie N. Epstein was Chief Financial Officer at Plastiq, Inc., Vice President-Finance for OnePIN, Inc., Controller & Vice President at Egenera, Inc., Principal at Coopers & Lybrand LLP, Corporate Controller at Organic, Inc., Chief Accounting Officer at Turbonomic, Inc. and Vice President of Fidelity Ventures Ltd.
She received an undergraduate degree from Harvard College and an MBA and a graduate degree from D'Amore-Mckim School of Business. |
| Richard Peters |
Dr. Richard Peters is a President, CEO, Secretary, Treasurer & Director at Yumanity Therapeutics, Inc., an Independent Director at Aprea Therapeutics, Inc. and a President, Chief Executive Officer & Director at Yumanity, Inc. He is on the Board of Directors at Yumanity Therapeutics, Inc., Aprea Therapeutics, Inc., PIC Therapeutics, Inc., Tellbio, Inc. and Yumanity, Inc. Dr. Peters was previously employed as a President, Chief Executive Officer & Director by Merrimack Pharmaceuticals, Inc., a Founder by X4 Pharmaceuticals, Inc. /Old/, a Co-Founder by X4 Pharmaceuticals, Inc., a Senior Vice President & Head-Global Rare Diseases by Genzyme Corp., a Senior Director by Onyx Pharmaceuticals, Inc., a Director-Medical Affairs by Amgen, Inc., and a Chief Executive Officer by MedNav, Inc. He received his undergraduate degree from the College of Charleston and a doctorate degree from Medical University of South Carolina. |
| Richard A. Heyman |
Richard A. Heyman is an entrepreneur and businessperson who founded 6 companies, notably: Syndax Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc. and Metacrine, Inc. and who has been at the helm of 7 different companies. Currently, Dr. Heyman holds the position of Chairman for PMV Pharmaceuticals, Inc., Chairman at Metacrine, Inc. (which he founded in 2014), Chairman of Amunix Pharmaceuticals, Inc. and Venture Partner at ARCH Venture Partners LLC. Dr. Heyman is also on the board of 11 other companies.
In the past Richard A. Heyman occupied the position of Vice President-Research at Ligand Pharmaceuticals, Inc., Senior Vice President-Drug Discovery at Kalypsys, Inc., President, CEO, Head-Research & Development at Aragon Pharmaceuticals, Inc. (he founded the company in 2009), President, Chief Executive Officer & Director at Seragon Pharmaceuticals, Inc. (he founded the company in 2013), Chief Scientific Officer & Senior VP-Research at X-Ceptor Therapeutics, Inc. (he founded the company in 1999) and Director at Syndax Pharmaceuticals, Inc.
Dr. Heyman received an undergraduate degree from the University of Connecticut and a doctorate from the University of Minnesota. |
| David A. Arkowitz |
David A. Arkowitz occupies the position of EVP, Chief Financial & Accounting Officer at Seres Therapeutics, Inc. Mr. Arkowitz is also on the board of Yumanity, Inc., F-star Therapeutics, Inc. and Yumanity Therapeutics, Inc.
Mr. Arkowitz previously held the position of Chief Financial & Accounting Officer of Flexion Therapeutics, Inc., VP & Controller-Research & Development Division at Merck & Co., Inc. Chief Financial Officer & Treasurer of Idenix Pharmaceuticals LLC, Vice President-Finance & Business Development at Merck Frosst Canada Ltd. Director-Financial Planning & Analysis at Merck-Medco Managed Care LLC and Controller at Merck Research Laboratories Massachusetts LLC (which are all subsidiaries of Merck & Co., Inc.), Chief Operating & Financial Officer at Visterra, Inc., Chief Financial Officer & General Manager at Mascoma Corp. and Chief Financial & Business Officer at AMAG Pharmaceuticals, Inc.
Mr. Arkowitz received an undergraduate degree from Brandeis University and an MBA from Columbia Business School. |
| Lynne Zydowsky |
Founder of Renovis, Inc., Zydowsky Consultants LLC and Alexandria Summit, Lynne Zydowsky is an entrepreneur who holds the position of President at Alexandria Summit, President for Zydowsky Consultants LLC, Chief Science Officer at Alexandria Real Estate Equities, Inc. and Chief Scientific Officer at Alexandria Agtech. Dr. Zydowsky is also on the board of Butler University, Reagan-udall Foundation and Yumanity Therapeutics, Inc. and Member-West Coast Board at buildOn, Inc., Member-Discovery Council at Harvard Medical School and Member-Observer Board at Onefifteen Health & Onefifteen Recovery.
In her past career Lynne Zydowsky occupied the position of VP-Pharmaceutical Business Development at Exelixis, Inc., Chief Operations Officer for Renovis, Inc. and Chief Operating Officer for Ikaria, Inc.
She received a doctorate from The Ohio State University and an undergraduate degree from Butler University. |
| Cecil B. Pickett |
Dr. Cecil B. Pickett is an Independent Director at Yumanity Therapeutics, Inc., a Member at Institute of Medicine and a Member-Medicine Institute at National Academy of Sciences. He is on the Board of Directors at Yumanity, Inc., Zimmer US, Inc. and Yumanity Therapeutics, Inc. Dr. Pickett was previously employed as an Independent Director by Zimmer Biomet Holdings, Inc., a President by Biogen Idec New Ventures, Inc., a Director & President-Research & Development by Biogen Idec, Inc. (North Carolina), a President-Research & Development by Biogen Idec, Inc., a President & Senior Vice President by Schering-Plough Research Institute, a Senior Vice President by Schering-Plough Corp., and a Director-Molecular Pharmacology & BioChemistry by Merck & Co., Inc. He also served on the board at Purdue Pharma LP and Yumanity Holdings LLC. He received his undergraduate degree from California State University-East Bay and a doctorate degree from the University of California, Los Angeles. |
| Kimberlee Cobleigh Drapkin |
Kimberlee Cobleigh Drapkin occupies the position of Chief Financial Officer & Treasurer of Jounce Therapeutics, Inc. She is also on the board of Yumanity, Inc. and Yumanity Therapeutics, Inc.
In her past career she was Chief Financial Officer for EPIX Pharmaceuticals, Inc. Chief Financial Officer of Predix Pharmaceuticals, Inc. and Chief Financial Officer for Predix Pharmaceuticals Holdings, Inc. (both are subsidiaries of EPIX Pharmaceuticals, Inc.), Chief Financial Officer for NinePoint Medical, Inc., Chief Financial Officer of Edimer Pharmaceuticals, Inc., Chief Financial Officer for Sesen Bio, Inc., Chief Financial Officer of Blueprint Medicines Corp., Chief Financial Officer & Treasurer for Voyager Therapeutics, Inc., Chief Financial Officer & Owner at Kcd Financial Consultants LLC, Chief Financial Officer at Avila Therapeutics, Inc., Chief Financial Officer of Warp Drive Bio, Inc., Principal at Millennium Pharmaceuticals, Inc. and Principal at PricewaterhouseCoopers LLP.
Ms. Drapkin received an undergraduate degree from Babson College. |
| Patricia L. Allen |
Patricia L. Allen occupies the position of Chief Financial Officer at Vividion Therapeutics, Inc. She is also on the board of 7 other companies.
In her past career Ms. Allen occupied the position of Treasurer & Vice President for Alnylam Pharmaceuticals, Inc., Finance Director for Alkermes, Inc., CFO, Treasurer & Principal Accounting Officer at Zafgen, Inc. and Auditor for Deloitte & Touche LLP.
Patricia L. Allen received an undergraduate degree from Bryant University. |
| Jeffery W. Kelly |
Jeffery W. Kelly is an entrepreneur who founded 5 companies, notably: Yumanity Therapeutics, Inc. Proteostasis Therapeutics, Inc. and Protego Biopharma Dr. Kelly is on the board of The Scripps Research Institute and 4 other companies. |
